Ryan Logue
Pulmonary Disease · Indianapolis, INNPI 1093178477
Payments from drug & device makers
Across 552 payments — averaging $54.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$19K
- AstraZeneca$2K
- Sanofi$1K
- Boehringer Ingelheim$947
- Regeneron Healthcare Solutions, Inc.$841
- Actelion Pharmaceuticals US, Inc.$699
- plus $5K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 107 | $19,254 |
| AstraZeneca | 89 | $2,283 |
| Sanofi | 51 | $1,341 |
| Boehringer Ingelheim | 42 | $947 |
| Regeneron Healthcare Solutions, Inc. | 34 | $841 |
| Actelion Pharmaceuticals US, Inc. | 27 | $699 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $650 |
| Grifols USA, LLC | 21 | $451 |
| Insmed, Inc. | 18 | $318 |
| United Therapeutics Corporation | 13 | $312 |
| Amgen | 14 | $297 |
| AbbVie | 11 | $287 |
| Mallinckrodt Hospital Products Inc. | 10 | $233 |
| Johnson & Johnson | 13 | $206 |
| Medical Device Business Services, Inc. | 3 | $199 |
| Mylan Specialty L.p. | 12 | $193 |
| Inari Medical, Inc. | 1 | $178 |
| Philips North America LLC | 9 | $157 |
| Gilead | 7 | $145 |
| Viatris Specialty LLC | 5 | $109 |
| Verona Pharma, Inc. | 5 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Inogen, Inc. | 5 | $93 |
| Novartis | 5 | $88 |
| Merck | 4 | $69 |
| Advanced Respiratory, Inc | 2 | $69 |
| Bayer | 3 | $58 |
| Astellas Pharma US Inc | 2 | $44 |
| Pfizer | 2 | $37 |
| Pulmonx Corporation | 2 | $37 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Electromed, Inc. | 2 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$29,870 in reported general payments places this provider in the 85th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Indianapolis
- Cynthia BrownIndianapolis$7.3M
- Roberto MachadoIndianapolis$219K
- Michael DuncanIndianapolis$146K
- Gary ZalogaIndianapolis$79K
- Abboud KawakIndianapolis$68K
- George RubeizIndianapolis$24K
- Clare ProhaskaIndianapolis$20K
- Rajat NarangIndianapolis$17K
- Marcus TielkerIndianapolis$11K
- Imad ShawaGreenwood$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.